- Home
- PAVM vs BRTX Comparison
PAVM vs BRTX Comparison
Compare PAVM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | BRTX |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 9.7M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAVM | BRTX |
|---|---|---|
| Price | $7.15 | $1.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $510.00 | N/A |
| AVG Volume (30 Days) | 22.1K | ★ 34.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $29,000.00 | ★ $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | $450.56 | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $6.00 | $0.98 |
| 52 Week High | $26.85 | $2.55 |
Technical Indicators
Market Signals| Indicator | PAVM | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 92.38 | 50.05 |
| Support Level | $0.21 | $1.00 |
| Resistance Level | $9.26 | $1.28 |
| Average True Range (ATR) | 0.36 | 0.09 |
| MACD | 0.81 | 0.01 |
| Stochastic Oscillator | 74.74 | 60.74 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.